FDA, HHS Taking Action Against Telehealth’s Compounded Drug Advertising

Lexology September 29, 2025
Holland & Knight LLP

Highlights

• The U.S. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services (HHS) have announced a broad initiative to “rein in misleading direct-to-consumer pharmaceutical advertisements.”
• Notably, in addition to drug companies, the FDA issued warning letters to telehealth providers and companies, including several glucagon-like peptide-1 (GLP-1) telehealth providers.

The U.S. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services (HHS) on Sept. 9, 2025, announced a broad initiative to “rein in misleading direct-to-consumer pharmaceutical advertisements.” In its press release, the FDA said it was “sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.”

The FDA published these...

Today's Sponsors

Today's Sponsor